Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
Natco Pharma intends to defend the matter accordingly
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
This agreement paves the way for the introduction of YESAFILI into the Canadian market
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
AMI to become part of Enpro’s Sealing Technologies Segment
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
Subscribe To Our Newsletter & Stay Updated
